A Phase 1/2 Study of Pembrolizumab Plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphomas
Phase of Trial: Phase I/II
Latest Information Update: 22 Nov 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary) ; Pralatrexate (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 05 Mar 2019 Status changed from not yet recruiting to recruiting.
- 17 Dec 2018 Planned initiation date changed from 27 Oct 2018 to 27 Mar 2019.
- 01 Aug 2018 New trial record